FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205902564> ?p ?o ?g. }

• W4205902564 endingPage "e10" @default.
• W4205902564 startingPage "e9" @default.
• W4205902564 abstract "Purpose/Objective(s): • Platinum-based chemotherapy with pemetrexed is an appropriate first line treatment option for unresectable malignant pleural mesothelioma (MPM) • The DREAM¹ and PrE0505² Phase II trials combined durvalumab (PD-L1 inhibitor) with a platinum and pemetrexed both exceeding pre-specified response with acceptable toxicity • CheckMate 7433 recently reported an overall survival benefit with ipilimumab plus nivolumab vs. chemotherapy (HR 0.74, 95% CI 0.50 to 0.91). However, this benefit was less apparent in the 75% of patients with epithelioid histology (HR 0.86, 95% CI 0.69 to 1.08) • Clinical trials to further explore optimal first line treatment for MPM with immunotherapy are needed Materials/Methods International, open label, randomised (2:1), multi-centre, phase 3 trial • 480 patients (320 durvalumab and chemotherapy, 160 chemotherapy) to be recruited over 27 months and followed for another 24 months • This provides over 85% power if the true hazard ratio for overall survival is 0.70 with 2-sided alpha of 0.05, assuming a median survival of 15 months in the chemotherapy group, 21.4 months in the durvalumab and chemotherapy group, with an allowance for crossover Results TBD Conclusion TBD Purpose/Objective(s): • Platinum-based chemotherapy with pemetrexed is an appropriate first line treatment option for unresectable malignant pleural mesothelioma (MPM) • The DREAM¹ and PrE0505² Phase II trials combined durvalumab (PD-L1 inhibitor) with a platinum and pemetrexed both exceeding pre-specified response with acceptable toxicity • CheckMate 7433 recently reported an overall survival benefit with ipilimumab plus nivolumab vs. chemotherapy (HR 0.74, 95% CI 0.50 to 0.91). However, this benefit was less apparent in the 75% of patients with epithelioid histology (HR 0.86, 95% CI 0.69 to 1.08) • Clinical trials to further explore optimal first line treatment for MPM with immunotherapy are needed International, open label, randomised (2:1), multi-centre, phase 3 trial • 480 patients (320 durvalumab and chemotherapy, 160 chemotherapy) to be recruited over 27 months and followed for another 24 months • This provides over 85% power if the true hazard ratio for overall survival is 0.70 with 2-sided alpha of 0.05, assuming a median survival of 15 months in the chemotherapy group, 21.4 months in the durvalumab and chemotherapy group, with an allowance for crossover TBD TBD" @default.
• W4205902564 created "2022-01-25" @default.
• W4205902564 creator A5003030864 @default.
• W4205902564 creator A5014084163 @default.
• W4205902564 creator A5018401879 @default.
• W4205902564 creator A5020977811 @default.
• W4205902564 creator A5025018030 @default.
• W4205902564 creator A5033519199 @default.
• W4205902564 creator A5046891733 @default.
• W4205902564 creator A5048952656 @default.
• W4205902564 creator A5056510071 @default.
• W4205902564 creator A5059543131 @default.
• W4205902564 creator A5061361406 @default.
• W4205902564 creator A5061757629 @default.
• W4205902564 creator A5064012830 @default.
• W4205902564 creator A5071194831 @default.
• W4205902564 creator A5085372050 @default.
• W4205902564 creator A5088178599 @default.
• W4205902564 creator A5090156519 @default.
• W4205902564 date "2022-02-01" @default.
• W4205902564 modified "2023-09-26" @default.
• W4205902564 title "DREAM3R: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma: A Phase 3 Randomised Trial" @default.
• W4205902564 doi "https://doi.org/10.1016/j.ijrobp.2021.10.177" @default.
• W4205902564 hasPublicationYear "2022" @default.
• W4205902564 type Work @default.
• W4205902564 citedByCount "0" @default.
• W4205902564 crossrefType "journal-article" @default.
• W4205902564 hasAuthorship W4205902564A5003030864 @default.
• W4205902564 hasAuthorship W4205902564A5014084163 @default.
• W4205902564 hasAuthorship W4205902564A5018401879 @default.
• W4205902564 hasAuthorship W4205902564A5020977811 @default.
• W4205902564 hasAuthorship W4205902564A5025018030 @default.
• W4205902564 hasAuthorship W4205902564A5033519199 @default.
• W4205902564 hasAuthorship W4205902564A5046891733 @default.
• W4205902564 hasAuthorship W4205902564A5048952656 @default.
• W4205902564 hasAuthorship W4205902564A5056510071 @default.
• W4205902564 hasAuthorship W4205902564A5059543131 @default.
• W4205902564 hasAuthorship W4205902564A5061361406 @default.
• W4205902564 hasAuthorship W4205902564A5061757629 @default.
• W4205902564 hasAuthorship W4205902564A5064012830 @default.
• W4205902564 hasAuthorship W4205902564A5071194831 @default.
• W4205902564 hasAuthorship W4205902564A5085372050 @default.
• W4205902564 hasAuthorship W4205902564A5088178599 @default.
• W4205902564 hasAuthorship W4205902564A5090156519 @default.
• W4205902564 hasConcept C121608353 @default.
• W4205902564 hasConcept C126322002 @default.
• W4205902564 hasConcept C141071460 @default.
• W4205902564 hasConcept C142724271 @default.
• W4205902564 hasConcept C143998085 @default.
• W4205902564 hasConcept C207103383 @default.
• W4205902564 hasConcept C2776694085 @default.
• W4205902564 hasConcept C2777240266 @default.
• W4205902564 hasConcept C2777407522 @default.
• W4205902564 hasConcept C2777701055 @default.
• W4205902564 hasConcept C2777742743 @default.
• W4205902564 hasConcept C2778239845 @default.
• W4205902564 hasConcept C2780030458 @default.
• W4205902564 hasConcept C2780258809 @default.
• W4205902564 hasConcept C44249647 @default.
• W4205902564 hasConcept C71924100 @default.
• W4205902564 hasConceptScore W4205902564C121608353 @default.
• W4205902564 hasConceptScore W4205902564C126322002 @default.
• W4205902564 hasConceptScore W4205902564C141071460 @default.
• W4205902564 hasConceptScore W4205902564C142724271 @default.
• W4205902564 hasConceptScore W4205902564C143998085 @default.
• W4205902564 hasConceptScore W4205902564C207103383 @default.
• W4205902564 hasConceptScore W4205902564C2776694085 @default.
• W4205902564 hasConceptScore W4205902564C2777240266 @default.
• W4205902564 hasConceptScore W4205902564C2777407522 @default.
• W4205902564 hasConceptScore W4205902564C2777701055 @default.
• W4205902564 hasConceptScore W4205902564C2777742743 @default.
• W4205902564 hasConceptScore W4205902564C2778239845 @default.
• W4205902564 hasConceptScore W4205902564C2780030458 @default.
• W4205902564 hasConceptScore W4205902564C2780258809 @default.
• W4205902564 hasConceptScore W4205902564C44249647 @default.
• W4205902564 hasConceptScore W4205902564C71924100 @default.
• W4205902564 hasIssue "2" @default.
• W4205902564 hasLocation W42059025641 @default.
• W4205902564 hasOpenAccess W4205902564 @default.
• W4205902564 hasPrimaryLocation W42059025641 @default.
• W4205902564 hasRelatedWork W2060595379 @default.
• W4205902564 hasRelatedWork W2074305818 @default.
• W4205902564 hasRelatedWork W2115425935 @default.
• W4205902564 hasRelatedWork W2136894251 @default.
• W4205902564 hasRelatedWork W2183430738 @default.
• W4205902564 hasRelatedWork W2404692521 @default.
• W4205902564 hasRelatedWork W2897565471 @default.
• W4205902564 hasRelatedWork W3129950743 @default.
• W4205902564 hasRelatedWork W4223442529 @default.
• W4205902564 hasRelatedWork W4254666574 @default.
• W4205902564 hasVolume "112" @default.
• W4205902564 isParatext "false" @default.
• W4205902564 isRetracted "false" @default.
• W4205902564 workType "article" @default.